Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4

Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4

Maxim Group has upgraded its rating for Coherus Oncology (NASDAQ: CHRS) to "Buy" and set a price target (PT) of $4.00. The upgrade comes amidst positive developments for the company, including its participation in upcoming investor conferences and recent stock price appreciation [1].

Coherus Oncology, a fully integrated commercial-stage innovative oncology company, announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025. All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days [1].

The stock price of Coherus BioSciences has shown significant growth, rising by 5.88% on Wednesday, September 3, 2025, from $1.19 to $1.26. The stock has gained 43.13% since August 11, 2025, and has been on a strong upward trend, with positive technical signals from Moving Averages and MACD [2].

Maxim Group's upgrade reflects the company's strong fundamentals, including its approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a promising pipeline of proprietary candidates targeting various cancers. The company's strategy to grow sales of LOQTORZI and advance the development of new indications is expected to drive sales multiples and synergies from proprietary combinations [1].

Investors interested in Coherus Oncology's upcoming presentations or one-on-one meetings with management should contact their respective bank representatives. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, visit the Coherus website [1].

References:
[1] https://www.stocktitan.net/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-tj4ax1swcqgp.html
[2] https://stockinvest.us/stock/CHRS